Sugi Predict

Sugi Predict / Compounds / SCHEMBL24209

SCHEMBL24209

SCHEMBL24209

CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 1/20 0.78
▸ PGR P06401 1/20 0.78
▸ ADORA3 P0DMS8 1/20 0.78
▸ PTGS2 P35354 1/20 0.78
▸ PDE4D Q08499 1/20 0.78
▸ MGLL Q99685 1/20 0.74
▸ ALDH1A1 P00352 4/20 0.73
▸ CYP3A4 P08684 2/20 0.73
▸ ALOX15 P16050 2/20 0.73
▸ HSD17B10 Q99714 2/20 0.73
▸ TDP1 Q9NUW8 2/20 0.73
▸ TSHR P16473 1/20 0.73
▸ CNR1 P21554 4/20 0.72
▸ MAPT P10636 3/20 0.72
▸ THRB P10828 1/20 0.72
▸ FAAH O00519 3/20 0.67
▸ PPARG P37231 2/20 0.64
▸ HPGD P15428 2/20 0.64
▸ KDM4E B2RXH2 1/20 0.64
▸ MEN1 O00255 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4807962 1.00 NR1I2 (0.78) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL24208 1.00 NR1I2 (0.78) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL31264367 1.00 NR1I2 (0.78) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL20582488 1.00 NR1I2 (0.78) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL20582487 1.00 NR1I2 (0.78) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL6810935 0.98 ALDH1A1 (0.77) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL7796369 0.98 ALDH1A1 (0.77) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL5738380 0.98 ALDH1A1 (0.77) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL5738375 0.98 ALDH1A1 (0.77) NR1I2PGRADORA3PTGS2PDE4D
SCHEMBL29655825 0.98 NR1I2 (0.76) NR1I2PGRADORA3PTGS2PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213516-A1 Prophylactic Methods For Treating ALS BIOJIVA LLC 2025-07-03 — — US claimed
EP-4522147-A1 THERAPEUTIC METHODS FOR TREATING ALS Biojiva LLC (US) 2025-03-19 — — EP claimed
EP-4499061-A1 PROPHYLACTIC METHODS FOR TREATING ALS Biojiva LLC (US) 2025-02-05 — — EP claimed
CN-119286673-A Bacillus amyloliquefaciens for improving soy sauce color, inhibiting bacteria and enhancing aroma and application thereof 天津科技大学 2025-01-10 — — CN claimed
CN-118813730-A Preparation method of glyceride type polyunsaturated fatty acid 浙江医药股份有限公司新昌制药厂 2024-10-22 — — CN claimed
US-12109194-B2 Synergistic combination therapy for treating ALS BIOJIVA LLC (US) 2024-10-08 — — US claimed
US-20240216322-A1 COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2024-07-04 — — US claimed
CN-117264670-B Diesel antiwear agent and preparation method thereof 湖南浩润科技有限公司 2024-05-10 — — CN claimed
CN-117264670-A Diesel antiwear agent and preparation method thereof 湖南浩润科技有限公司 2023-12-22 — — CN claimed
WO-2023220058-A1 THERAPEUTIC METHODS FOR TREATING ALS RETROTOPE, INC. (US) 2023-11-16 — — WO claimed
US-20110218243-A1 COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE AMARIN PHARMA, INC. (US) 2011-09-08 — — US claimed
US-20110034555-A1 COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY AMARIN PHARMA , INC. (US) 2011-02-10 — — US claimed
WO-2010147994-A1 COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY AMARIN PHARMA, INC. (US) 2010-12-23 — — WO claimed
CN-101796014-A Production and purification of esters of polyunsaturated fatty acids MARTEK BIOSCIENCES CORP 2010-08-04 — — CN claimed
US-20070207503-A1 DETECTION OF ALCOHOL-ESTERIFIED FATTY ACIDS DETROIT R&D 2007-09-06 — — US claimed
WO-2006083434-A1 USE OF ARACHIDONIC ACID AND ITS DERIVATIVES FOR INCREASING SKELETAL MUSCLE MASS LLEWELLYN WILLIAM C (US) 2006-08-10 — — WO claimed
US-20050137256-A1 Use of arachidonic acid as a method of increasing skeletal muscle mass LLEWELLYN WILLIAM C (US) 2005-06-23 — — US claimed
US-20010041365-A1 Methods for monitoring alcohol consumption GENERAL HOSPITAL CORPORATION, THE 2001-11-15 — — US claimed
US-5411751-A Enteric administering nutrients with medium chain fatty acids to protect intestines RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-05-02 — — US claimed
WO-1993020717-A2 REDUCING GASTROINTESTINAL IRRITATION IN INFANT NUTRITION RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-10-28 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213516-A1 Prophylactic Methods For Treating ALS ALOX12, ALOX15B, ALOX15 NR1I2 3917/4885PGR 3206/4885ADORA3 1563/4885
US-12109194-B2 Synergistic combination therapy for treating ALS SMN1; SMN2, ALOX12, ALOX15 NR1I2 1971/4885PGR 2224/4885ADORA3 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.